Kazia Therapeutics Limited (KZIA) 20-F 2007 FY Annual report (foreign)

Exhibit 13.1

Certification
Pursuant to Section 302
The Sarbanes-Oxley Act of 2002

Each of Christopher Naughton, Managing Director, and David Ross Seaton, Chief Financial Officer of Novogen Limited, a New South Wales corporation (the “Company”), hereby certifies that:

(1)	The Company’s periodic report on form 20-F for the period ended June 30, 2007 (the “Form 20-F”) fully complies with the requirements of section 13(a) of the Securities Exchange Act of 1934 as amended; and
(2)	The information contained in the Form 20-F fairly presents, in all material respects, the financial condition and results of operations of the Company.

* * *

Managing Director	Chief Financial Officer
/s/ Christopher Naughton	/s/ David Seaton
Christopher Naughton	David Seaton
Date: December 14, 2007	Date: December 14, 2007

159